Triangle Biotechnology — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Triangle Biotechnology is a private, pre-revenue company developing a proprietary acoustic-assisted magnetic particle (AAMP) technology platform to address critical bottlenecks in life science sample preparation. Founded in 2000 and led by a team with deep expertise in ultrasonics and epigenetics, the company targets the high-growth NGS and epigenetics research markets with tools designed for high throughput, consistency, and cost-effectiveness. Its business model is centered on selling instruments and consumables to research laboratories, positioning it as an enabling technology provider within the broader diagnostics and research tools sector.

DiagnosticsInfectious Disease

Technology Platform

Proprietary AAMP™ (Acoustic-Assisted Magnetic Particle) technology that uses ultrasonic energy and specialized reagents to enable high-throughput, precise, and affordable shearing of DNA and chromatin for next-generation sequencing and epigenetics research.

Opportunities

The rapid growth of the NGS and epigenetics research markets creates strong demand for improved sample prep tools that are faster, more consistent, and scalable.

Triangle Bio's technology addresses a clear bottleneck, positioning it to capture market share from traditional, cumbersome methods.

Its platform approach allows for expansion into multiple adjacent sample prep applications beyond DNA and chromatin shearing.

Risk Factors

The company faces significant competition from established, well-funded life science tools giants.

As a pre-revenue private company, it carries funding and execution risk in commercializing its technology.

Success depends on convincing a conservative research community to adopt a new platform, requiring clear demonstrations of superior performance and ease of use.

Competitive Landscape

Triangle Biotechnology competes in the life science sample preparation market, which is dominated by large players like Thermo Fisher Scientific, QIAGEN, Bio-Rad, and Covaris. Its differentiation is based on claims of higher throughput, better yield, and lower cost compared to conventional sonication and enzymatic methods. It must carve out a niche by targeting specific pain points in NGS and ChIP-Seq workflows that are inadequately addressed by the broad portfolios of the incumbents.

More companies in Biologics / Biosimilars →More companies in United States →